Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma
Clinical trial NCT06348264 · RECRUITING
Trial details
- NCT number
- NCT06348264
- Sponsor
- Peking University First Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-10-10
- Primary completion
- 2029-03-30
- Enrollment
- 37
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.